ArticleJournal of pediatric surgery2019
Potential role of stem cells in disease prevention based on a murine model of experimental necrotizing enterocolitis.
Article in Journal of pediatric surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cell-based therapies in preclinical models of necrotizing enterocolitis: a systematic review and meta-analysis.Stem cells translational medicine · 2025Pooled it
- Intraperitoneal rescue stem cell therapy in experimental NEC mitigates intestinal, pulmonary, and neuroinflammatory injury in mice.Pediatric research · 2026Article
- Necrotizing enterocolitis.Nature reviews. Disease primers · 2026Review
- Review
- Administration of Adipose-Derived Stem Cells Lowers the Initial Levels of IL6 and TNF-Alpha in the Rat Model of Necrotizing Enterocolitis.International journal of molecular sciences · 2025Article
- Mapping the Landscape of Mesenchymal Stem Cell-Derived Extracellular Vesicles: From Bench to Bedside.Stem cells international · 2025Article
- Article
- Translating regenerative medicine therapies in neonatal necrotizing enterocolitis.Pediatric research · 2024Article
- Administration of Adipose Tissue Derived Stem Cells before the Onset of the Disease Lowers the Levels of Inflammatory Cytokines IL-1 and IL-6 in the Rat Model of Necrotizing Enterocolitis.International journal of molecular sciences · 2024Article
- Potential therapeutic effects of milk-derived exosomes on intestinal diseases.Journal of nanobiotechnology · 2023Review
- Research Models to Mimic Necrotizing Enterocolitis and Inflammatory Bowel Diseases: Focus on Extracellular Vesicles Action.Stem cells (Dayton, Ohio) · 2023Review
- Stem cell derived therapies to preserve and repair the developing intestine.Seminars in perinatology · 2023Article
- Programmed death of intestinal epithelial cells in neonatal necrotizing enterocolitis: a mini-review.Frontiers in pediatrics · 2023Review
- Stem cell therapy as a promising strategy in necrotizing enterocolitis.Molecular medicine (Cambridge, Mass.) · 2022Review
- Current therapy option for necrotizing enterocolitis: Practicalities and challenge.Frontiers in pediatrics · 2022Review
- Review
- Recent Advances in Necrotizing Enterocolitis Research: Strategies for Implementation in Clinical Practice.Clinics in perinatology · 2020Review
- The emerging role of exosomes in the pathogenesis, prognosis and treatment of necrotizing enterocolitis.American journal of translational research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundNecrotizing enterocolitis (NEC) is a devastating disease of newborns, and despite years of research, there is no known cure. The mortality rate of infants with NEC remains as high as 20%-30%. Babies who survive NEC frequently have long term complications including short gut syndrome, developmental delays and neurological sequelae. Unfortunately, despite much research over the past years, the precise pathogenesis of the disease is still not completely understood.
methodsOur laboratory has focused on identifying novel therapies to prevent the disease, including the use of stem cells (SC), heparin-binding epidermal growth factor-like growth factor (HB-EGF) and recently, stem cell derived-exosomes, a type of nanovesicle, to combat this illness.
resultsWe have outlined the major SC lines and data suggesting potential benefit as a curative or preventive approach for NEC as well as describing several new therapeutic strategies, including stem cell derived- exosomes and HB-EGF for decreasing the incidence and severity of this disease in rat models in our lab.
conclusionOverall, our lab has demonstrated that these different types of SC equivalently reduce the incidence and severity of NEC and equally preserve intestinal barrier function during NEC. We have previously demonstrated that AF-MSC can protect the intestines from intestinal injury and may therefore hold strong therapeutic potential for the prevention of NEC. Most recently, our work with stem cell derived-exosomes has shown them to be equivalent to their derived SC lines in decreasing the incidence of this disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.